Answers are grounded in this paper and cite their sources.
Among patients with node-positive tumors, ER-negative breast cancer, biweekly doxorubicin/cyclophosphamide plus paclitaxel lowers the rate of recurrence and death by more than 50% in comparison with low-dose cyclophosphamide, doxorubicin, and fluorouracil as used in the first study.
No takes yet. Share an insight, caveat, or question.
Berry et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: